Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Urinary Tract Infection

  Free Subscription


Articles published in J Antimicrob Chemother

Retrieve available abstracts of 49 articles:
HTML format



Single Articles


    February 2024
  1. BAYART J, Drouet J, Peycelon M, Mariani P, et al
    Temocillin for febrile urinary tract infections caused by ESBL-producing Enterobacteriaceae in children: a monocentric exposed/non-exposed study.
    J Antimicrob Chemother. 2024 Feb 27:dkae053. doi: 10.1093.
    PubMed     Abstract available


  2. PIAZZOLLA HRW, Modin F, Halkjaer SI, Petersen AM, et al
    The association between bacteriuria and adverse pregnancy outcomes: a systematic review and meta-analysis of observational studies.
    J Antimicrob Chemother. 2024;79:241-254.
    PubMed     Abstract available


    January 2024
  3. MONTELIN H, Camporeale A, Hallgren A, Angelin M, et al
    Treatment, outcomes and characterization of pathogens in urinary tract infections caused by ESBL-producing Enterobacterales: a prospective multicentre study.
    J Antimicrob Chemother. 2024 Jan 10:dkad402. doi: 10.1093.
    PubMed     Abstract available


  4. ARYEE A, Rockenschaub P, Robson J, Ahmed Z, et al
    Assessing the impact of discordant antibiotic treatment on adverse outcomes in community-onset UTI: a retrospective cohort study.
    J Antimicrob Chemother. 2024;79:134-142.
    PubMed     Abstract available


    December 2023
  5. HATTORI Y, Tahara S, Aso S, Makito K, et al
    Comparison of prophylactic antibiotics for endonasal transsphenoidal surgery using a national inpatient database in Japan.
    J Antimicrob Chemother. 2023;78:2909-2914.
    PubMed     Abstract available


    November 2023
  6. KASHOURIS E, Joseph A, Lewis T
    Nitrofurantoin: what is the evidence for current UK guidance?
    J Antimicrob Chemother. 2023;78:2605-2611.
    PubMed     Abstract available


  7. TORRES A, Wible M, Tawadrous M, Irani P, et al
    Efficacy and safety of ceftazidime/avibactam in patients with infections caused by beta-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme.
    J Antimicrob Chemother. 2023;78:2672-2682.
    PubMed     Abstract available


    September 2023
  8. NGUYEN HM, Flerchinger S, Smith JR, Felcher AH, et al
    Diagnostic and antibiotic stewardship lessons: an outpatient assessment of symptomatic reflex urinalysis ordering accuracy using an electronic best-practice alert.
    J Antimicrob Chemother. 2023;78:2283-2290.
    PubMed     Abstract available


    August 2023
  9. CARTER C, Hutchison A, Rudder S, Trotter E, et al
    Uropathogenic Escherichia coli population structure and antimicrobial susceptibility in Norfolk, UK.
    J Antimicrob Chemother. 2023;78:2028-2036.
    PubMed     Abstract available


    July 2023
  10. FANSHAWE TR, Judge RK, Mort S, Butler CC, et al
    Evidence-based appraisal of two guidelines for the diagnosis of suspected, uncomplicated urinary tract infections in primary care: a diagnostic accuracy validation study.
    J Antimicrob Chemother. 2023 Jul 4:dkad212. doi: 10.1093.
    PubMed     Abstract available


    June 2023
  11. SOJO-DORADO J, Lopez-Hernandez I, Hernandez-Torres A, Retamar-Gentil P, et al
    Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial.
    J Antimicrob Chemother. 2023 Jun 1:dkad147. doi: 10.1093.
    PubMed     Abstract available


  12. MAHER JM, Huband MD, Blankers CG, Puttagunta S, et al
    In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program.
    J Antimicrob Chemother. 2023;78:1406-1414.
    PubMed     Abstract available


    May 2023
  13. PURCELL R, Yeoh D, Bowen A, Britton PN, et al
    A multicentre, retrospective audit of fosfomycin use for urinary tract infections in Australian children and adolescents.
    J Antimicrob Chemother. 2023 May 16:dkad131. doi: 10.1093.
    PubMed     Abstract available


    March 2023
  14. WATKINS RR, Thapaliya D, Lemonovich TL, Bonomo RA, et al
    Gepotidacin: a novel, oral, 'first-in-class' triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea.
    J Antimicrob Chemother. 2023 Mar 8:dkad060. doi: 10.1093.
    PubMed     Abstract available


    February 2023
  15. VALLEE M, Harding C, Hall J, Aldridge PD, et al
    Exploring the in situ evolution of nitrofurantoin resistance in clinically derived uropathogenic Escherichia coli isolates.
    J Antimicrob Chemother. 2023;78:373-379.
    PubMed     Abstract available


  16. ABBOTT IJ, van Gorp E, Cottingham H, Macesic N, et al
    Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model.
    J Antimicrob Chemother. 2023;78:397-410.
    PubMed     Abstract available


    January 2023
  17. CHEN L, Hua J, Hong SJ, Yuan CY, et al
    Comparison of the relative efficacy of beta-lactam/beta-lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational coh
    J Antimicrob Chemother. 2023 Jan 24:dkac448. doi: 10.1093.
    PubMed     Abstract available


    December 2022
  18. FRIMODT-MOLLER N, Simonsen GS, Larsen AR, Kahlmeter G, et al
    Pivmecillinam, the paradigm of an antibiotic with low resistance rates in Escherichia coli urine isolates despite high consumption.
    J Antimicrob Chemother. 2022;78:289-295.
    PubMed     Abstract available


    November 2022
  19. GUO S, Li X, Li Y, Tong H, et al
    Sitafloxacin pharmacokinetics/pharmacodynamics against multidrug-resistant bacteria in a dynamic urinary tract infection in vitro model.
    J Antimicrob Chemother. 2022 Nov 4. pii: 6795394. doi: 10.1093.
    PubMed     Abstract available


    September 2022
  20. WALKTY AJ, Karlowsky JA, Baxter MR, Lagace-Wiens PRS, et al
    In vitro activity of sulopenem against 1880 bacterial pathogens isolated from Canadian patients with urinary tract infections (CANWARD, 2014-21).
    J Antimicrob Chemother. 2022 Sep 30. pii: 6731707. doi: 10.1093.
    PubMed     Abstract available


    July 2022
  21. EMERAUD C, Godmer A, Girlich D, Vanparis O, et al
    Activity of mecillinam against carbapenem-resistant Enterobacterales.
    J Antimicrob Chemother. 2022 Jul 11. pii: 6639593. doi: 10.1093.
    PubMed     Abstract available


    April 2022
  22. ABBOTT IJ, van Gorp E, Wyres KL, Wallis SC, et al
    Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.
    J Antimicrob Chemother. 2022;77:1324-1333.
    PubMed     Abstract available


  23. FUCHS F, Becerra-Aparicio F, Xanthopoulou K, Seifert H, et al
    In vitro activity of nitroxoline against carbapenem-resistant Acinetobacter baumannii isolated from the urinary tract.
    J Antimicrob Chemother. 2022 Apr 12. pii: 6566767. doi: 10.1093.
    PubMed     Abstract available


    March 2022
  24. NEVILLE LF, Shalit I, Warn PA, Rendell JT, et al
    Vancomycin-arginine (STM-001) abrogates ESBL carrier and carbapenem-resistant Escherichia coli burden in a murine complicated urinary tract infection model.
    J Antimicrob Chemother. 2022 Mar 1. pii: 6539950. doi: 10.1093.
    PubMed     Abstract available


    February 2022
  25. ELIAS P, Barraud O, El Hamel C, Chainier D, et al
    Integron detection for prediction of trimethoprim/sulfamethoxazole susceptibility in children with Enterobacterales urinary tract infections.
    J Antimicrob Chemother. 2022;77:767-770.
    PubMed     Abstract available


    November 2021
  26. LASKO MJ, Nicolau DP, Asempa TE
    Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model.
    J Antimicrob Chemother. 2021 Nov 8. pii: 6423104. doi: 10.1093.
    PubMed     Abstract available


  27. DELORY T, Le Bel J, Lariven S, Peiffer-Smadja N, et al
    Computerized decision support system (CDSS) use for surveillance of antimicrobial resistance in urinary tract infections in primary care.
    J Antimicrob Chemother. 2021 Nov 8. pii: 6423107. doi: 10.1093.
    PubMed     Abstract available


    September 2021
  28. ABBOTT IJ, Mouton JW, Peleg AY, Meletiadis J, et al
    Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints.
    J Antimicrob Chemother. 2021 Sep 2. pii: 6362682. doi: 10.1093.
    PubMed     Abstract available


    August 2021
  29. BIRGY A, Madhi F, Jung C, Levy C, et al
    Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections.
    J Antimicrob Chemother. 2021 Aug 28. pii: 6359118. doi: 10.1093.
    PubMed     Abstract available


  30. MOUNSEY O, Schubert H, Findlay J, Morley K, et al
    Limited phylogenetic overlap between fluoroquinolone-resistant Escherichia coli isolated on dairy farms and those causing bacteriuria in humans living in the same geographical region.
    J Antimicrob Chemother. 2021 Aug 27. pii: 6358704. doi: 10.1093.
    PubMed     Abstract available


    March 2021
  31. HENLY EL, Norris K, Rawson K, Zoulias N, et al
    Impact of long-term quorum sensing inhibition on uropathogenic Escherichia coli.
    J Antimicrob Chemother. 2021;76:909-919.
    PubMed     Abstract available


    February 2021
  32. ALEXANDRE K, Leysour de Rohello F, Dahyot S, Etienne M, et al
    Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study.
    J Antimicrob Chemother. 2021;76:784-788.
    PubMed     Abstract available


    January 2021
  33. BOEL JB, Antsupova V, Knudsen JD, Jarlov JO, et al
    Intravenous mecillinam compared with other beta-lactams as targeted treatment for Escherichia coli or Klebsiella spp. bacteraemia with urinary tract focus.
    J Antimicrob Chemother. 2021;76:206-211.
    PubMed     Abstract available


    December 2020
  34. LARRAMENDY S, Gaultier A, Fournier JP, Caillon J, et al
    Local characteristics associated with higher prevalence of ESBL-producing Escherichia coli in community-acquired urinary tract infections: an observational, cross-sectional study.
    J Antimicrob Chemother. 2020 Dec 22. pii: 6042378. doi: 10.1093.
    PubMed     Abstract available


    October 2020
  35. STEWART AG, Harris PNA, Henderson A, Schembri MA, et al
    Erratum to: Oral cephalosporin and beta-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections.
    J Antimicrob Chemother. 2020 Oct 28. pii: 5941854. doi: 10.1093.
    PubMed    


    August 2020
  36. RICHELSEN R, Smit J, Schonheyder HC, Laxsen Anru P, et al
    Outcome of community-onset ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and urinary tract infection: a population-based cohort study in Denmark.
    J Antimicrob Chemother. 2020 Aug 30. pii: 5899248. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  37. KUIPER SG, Dijkmans AC, Wilms EB, Kamerling IMC, et al
    Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection.
    J Antimicrob Chemother. 2020 Jul 26. pii: 5876615. doi: 10.1093.
    PubMed     Abstract available


    May 2020
  38. STEWART AG, Harris PNA, Henderson A, Schembri MA, et al
    Oral cephalosporin and beta-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections.
    J Antimicrob Chemother. 2020 May 22. pii: 5842233. doi: 10.1093.
    PubMed     Abstract available


  39. PAGANO P, Marra A, Shinabarger D, Pillar C, et al
    In vitro activity of omadacycline and levofloxacin against Escherichia coli, Klebsiella pneumoniae and Staphylococcus saprophyticus in human urine supplemented with calcium and magnesium.
    J Antimicrob Chemother. 2020 May 19. pii: 5840661. doi: 10.1093.
    PubMed     Abstract available


  40. MARTINEZ EP, van Rosmalen J, Bustillos R, Natsch S, et al
    Trends, seasonality and the association between outpatient antibiotic use and antimicrobial resistance among urinary bacteria in the Netherlands.
    J Antimicrob Chemother. 2020 May 17. pii: 5838345. doi: 10.1093.
    PubMed     Abstract available


  41. CHANAME PINEDO LE, Bruyndonckx R, Catry B, Latour K, et al
    Fluoroquinolone resistance in Escherichia coli isolates after exposure to non-fluoroquinolone antibiotics: a retrospective case-control study.
    J Antimicrob Chemother. 2020 May 12. pii: 5836063. doi: 10.1093.
    PubMed     Abstract available


  42. ABBOTT IJ, van Gorp E, Wijma RA, Dekker J, et al
    Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model.
    J Antimicrob Chemother. 2020 May 3. pii: 5828355. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  43. HATLEN TJ, Flor R, Nguyen MH, Lee GH, et al
    Oral fosfomycin use for pyelonephritis and complicated urinary tract infections: a 1 year review of outcomes and prescribing habits in a large municipal healthcare system.
    J Antimicrob Chemother. 2020 Apr 17. pii: 5821485. doi: 10.1093.
    PubMed     Abstract available


    January 2020
  44. FINDLAY J, Gould VC, North P, Bowker KE, et al
    Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017-18.
    J Antimicrob Chemother. 2020;75:65-71.
    PubMed     Abstract available


    December 2019
  45. ABBOTT IJ, Dekker J, van Gorp E, Wijma RA, et al
    Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections.
    J Antimicrob Chemother. 2019 Dec 24. pii: 5686404. doi: 10.1093.
    PubMed     Abstract available


  46. NUSSBAUMER-PROLL AK, Eberl S, Reiter B, Stimpfl T, et al
    Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections.
    J Antimicrob Chemother. 2019 Dec 3. pii: 5651068. doi: 10.1093.
    PubMed     Abstract available


    October 2019
  47. BIRGY A, Madhi F, Jung C, Levy C, et al
    Diversity and trends in population structure of ESBL-producing Enterobacteriaceae in febrile urinary tract infections in children in France from 2014 to 2017.
    J Antimicrob Chemother. 2019 Oct 16. pii: 5588579. doi: 10.1093.
    PubMed     Abstract available


    January 2019
  48. GRAHAM M, Walker DA, Haremza E, Morris AJ, et al
    RCPAQAP audit of antimicrobial reporting in Australian and New Zealand laboratories: opportunities for laboratory contribution to antimicrobial stewardship.
    J Antimicrob Chemother. 2019;74:251-255.
    PubMed     Abstract available


  49. BELAS A, Marques C, Aboim C, Pomba C, et al
    Emergence of Escherichia coli ST131 H30/H30-Rx subclones in companion animals.
    J Antimicrob Chemother. 2019;74:266-269.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Urinary Tract Infection is free of charge.